This application for continuation of the Specialized Program of Research Excellence (SPORE) in Gastrointestinal Cancer at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins supports a highly interactive, multidisciplinary, and inter-institutional program. Five research projects within three research themes, four cores, a career development and a research developmental program are proposed to extend our translational research In colorectal and pancreatic cancer. Theme 1: Epidemiology and Inborn risk (Project 1, Markers for risk in familial pancreatic cancer, Drs. Klein, Hruban, and Goggins) Theme 2: Management of risk (Project 2, Markers for screening and diagnosis, Drs. Goggins and Kinzler;Project 3, Diagnostic strategies and risk-assessment for pancreatic cysts, Drs. Kinzler, Maitra, and Goggins). Theme 3: Post-diagnostic management (Project 4, Tumor antigens for individual signatures and therapy, Drs. Jaffee, Kern, and lacobuzio-Donahue;Project 5, Access of therapeutic agents to cancer cells, Drs. Zhou, Kern, and lacobuzio-Donahue). The cores support the research programs (Core 1, Administration and Communication, Dr. Scott Kern;Core 2, Human Tissue Research and Logistics, Dr. Christine lacobuzio-Donahue;Core 3, Familial Cancer Registries, Dr. Frank Giardiello;Core 4, Statistics/Bioinformatics, Drs. Alison Klein. The Career Development Program (Dr. Scott Kern) aids the emergence of new investigators and the Research Developmental Program (Dr. Bert Vogelstein) provides rapid funding of innovative directions.
This research program provides a spectrum of capabilities, allowing broad research moving from the lab bench to the patient for improved diagnosis and care, and studies of gastrointestinal cancers that move back to the lab for fundamental understanding of their scientific basis.
|Hata, Tatsuo; Dal Molin, Marco; Suenaga, Masaya et al. (2016) Cyst Fluid Telomerase Activity Predicts the Histologic Grade of Cystic Neoplasms of the Pancreas. Clin Cancer Res 22:5141-5151|
|Childs, Erica J; Chaffee, Kari G; Gallinger, Steven et al. (2016) Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study. Cancer Epidemiol Biomarkers Prev 25:1185-91|
|Yachida, Shinichi; Wood, Laura D; Suzuki, Masami et al. (2016) Genomic Sequencing Identifies ELF3 as a Driver of Ampullary Carcinoma. Cancer Cell 29:229-40|
|Rucki, Agnieszka A; Foley, Kelly; Zhang, Pingbo et al. (2016) Heterogeneous stromal signaling within the tumor microenvironment controls the metastasis of pancreatic cancer. Cancer Res :|
|Faisal, Farzana; Tsai, Hua-Ling; Blackford, Amanda et al. (2016) Longer Course of Induction Chemotherapy Followed by Chemoradiation Favors Better Survival Outcomes for Patients With Locally Advanced Pancreatic Cancer. Am J Clin Oncol 39:18-26|
|Kumar, Abhijeet; Le, Dung T (2016) Hepatocellular Carcinoma Regression After Cessation of Immunosuppressive Therapy. J Clin Oncol 34:e90-2|
|Poruk, Katherine E; Blackford, Amanda L; Weiss, Matthew J et al. (2016) Circulating Tumor Cells Expressing Markers of Tumor Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma. Clin Cancer Res :|
|Masica, David L; Dal Molin, Marco; Wolfgang, Christopher L et al. (2016) A novel approach for selecting combination clinical markers of pathology applied to a large retrospective cohort of surgically resected pancreatic cysts. J Am Med Inform Assoc :|
|Poruk, Katherine E; Valero 3rd, Vicente; Saunders, Tyler et al. (2016) Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Ann Surg 264:1073-1081|
|Foley, Kelly; Kim, Victoria; Jaffee, Elizabeth et al. (2016) Current progress in immunotherapy for pancreatic cancer. Cancer Lett 381:244-51|
Showing the most recent 10 out of 795 publications